Audrey Whaley

[NASA Administrator Jared Isaacman @NASAAdmin]

We go where we need to be, and today that was @NASAKennedy.

Some of my senior engineers and I spent time at @blueorigin with @JeffBezos and @davill, speaking with the workforce and seeing the damage at LC-36 firsthand. I appreciated the opportunity to hear directly from those working through the aftermath and better understand the challenges ahead.

There is a lot of work to do, but this is exactly why people choose careers in aerospace, whether at NASA, Blue Origin, or across the industry. The talent in this field thrives under pressure and performs at its best when solving the toughest problems.

We have been saying for months at NASA that we are not going to sit on our hands and wait for the capabilities necessary to achieve the nation’s most pressing objectives. We are going to take an active role alongside our partners, just as we did in the 1960s, to overcome setbacks, remove obstacles, and deliver the intended outcomes.

@NASA is committed to helping the Blue team recover, continue to advance their lunar lander and get New Glenn back to launching as soon as safely possible.

America’s greatest achievements in space were never the result of avoiding setbacks. They came from overcoming them. We have done it before, and we will do it again🇺🇸

[Audrey Whaley @WhaleyAudrey]

@VJHemOnc MCL patients are so blessed to have you @michaelwangmd!
I know that my husband and I are so grateful for you and your terrific team! 💚

[VJHemOnc @VJHemOnc]

🚨 On May 13, 2026, the FDA granted accelerated approval to sonrotoclax for adults with R/R #MantleCellLymphoma after at least two prior lines of therapy, including a BTK inhibitor.

Find out all the details in our feature article:

📖 ➡️ https://t.co/8ns5AAIU52

Featuring a video interview with leading expert @michaelwangmd.🎥

#LYMsm #Lymphoma #HemOnc #Hematology

[Audrey Whaley @WhaleyAudrey]

@michaelwangmd Terrific news!! 💚

[Michael Wang, MD @michaelwangmd]

Today we have great news for our patients and their families affected by mantle cell lymphoma! FDA approved a second generation oral Bcl-2 inhibitor Sonrotoclax for relapsed mantle cell lymphoma, congratulations!!!

[BeOne Medicines @BeOneMedicines]

#News for #Investors and #Media: The U.S. FDA has granted accelerated approval for our foundational BCL2 inhibitor in relapsed/refractory mantle cell lymphoma — the first and only in R/R #MCL.

Full announcement: https://t.co/rr45qXXnzP

#Oncology #BeOneOnnovator

[Audrey Whaley @WhaleyAudrey]

@FOXNashville Is this really due to the Tennessee General Assembly passing legislation to shift control of major airport governing boards from local cities to the state government??? Control…

[Audrey Whaley @WhaleyAudrey]

@michaelwangmd We are so grateful that you did. 💚

[Audrey Whaley @WhaleyAudrey]

@RussellBivenTV He is risen indeed 🙌🏻

[UT MD Anderson @UTMDAnderson]

The @US_FDA has approved breuxcabtagene autoleucel for treating patients with relapsed or refractory mantle cell lymphoma, following a trial led by our Dr. Michael Wang.

Read more: https://t.co/cwaMzW2nRg #EndCancer

[Michael Wang, MD @michaelwangmd]

CAR T cell therapy in mantle cell lymphoma are usually done after BTK inhibition failure. Today FDA approved the usage of brexucabtagene autoleucel in patients who never received BTK inhibition. It is a great step forward!

[Audrey Whaley @WhaleyAudrey]

@BoLoudon 🙄

[Eric Daugherty @EricLDaugh]

🚨 WOW! Venezuela star Eugenio Suarez after they defeat USA in the World Baseball Classic

“God is good! ALL the glory is for Lord Jesus! He was with us the whole time. We have to glorify Him and put His name in front of EVERYTHING!” 🙏🏻

[Dave Limp @davill]

We hot fired New Glenn’s GS2 serial number five last night, with the BE-3U engines ramping up to 175K of thrust. Love seeing the continuous flow of GS2s on the Space Coast!

[Michael Wang, MD @michaelwangmd]

Currently approved CAR T therapies on lymphoma are made from the patient’s blood T cells, autologous CAR T cells. They are potent but at times toxic. Making CAR T cells from each patient is labor-intensive, costly and time consuming. There are also CAR T cell manufacture failures

[Michael Wang, MD @michaelwangmd]

To overcome limitations of auto CAR T cells, many tries to make allogeneic CAR T cells, T cells from other sources such as from a healthy donor. But allo CAR T cells are so far not as efficacious. Some think that allo T cells could never match auto T cells by biological nature.

[Michael Wang, MD @michaelwangmd]

Both auto or allo CAR T cells are made ex vivo, outside of human body in the lab. An exciting new tech is to bypass all the limitations of ex vivo manufacture by directly infuse the lentivirus vector into the blood and let the CAR T cells to be made inside the patient’s body.

[Michael Wang, MD @michaelwangmd]

First clinic in 2026 today, it is going to be an exciting year for research endeavors in mantle cell lymphoma. Stay tuned!

[UT MD Anderson @UTMDAnderson]

Our Dr. Michael Wang presented the results of two studies for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) at #ASH25. In one, he and his team found Sonrotoclax to be a promising option in those previously treated with a bruton tyrosine kinase (BTK) inhibitor. The other showed that Pirtobrutinib continues to demonstrate efficacy in heavily pre-treated patients, regardless of whether they had previously received a cBTK inhibitor.
@michaelwangmd #EndCancer

[Lymphoma Hub @lymphomahub]

CONGRESS | #ASH25 | PRESENTATION

Michael Wang shares final update from the phase I/II BRUIN study of pirtobrutinib in patients with MCL (N = 166).

ORR was 49.3% in patients who received prior cBTKi (n = 152) and 85.7% in cBTKi-naïve patients (n = 14). mDoR was 21.6 months and 42.7 months, respectively.
Most common AEs were fatigue, diarrhea, dyspnea, anemia and decreased platelet counts. Grade ≥3 TRAEs included anemia, decreased platelet counts and fatigue.

Follow our live feed for more updates: https://t.co/QvRGEzgS3d
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress @michaelwangmd @MDAndersonnews